Broadfin Capital’s Epirus Biopharmaceuticals EPRS Stock Holding History
Bought
Maintained
Sold
Other funds holding EPRS
Broadfin Capital's EPRS Position: Q2 2016 in Review
Broadfin Capital sold out of Epirus Biopharmaceuticals (EPRS) in Q2 2016, closing a stake of 1,079,543 shares — an estimated $2.9M sold.
Broadfin Capital first reported a position in EPRS in Q1 2015 and held it in 5 quarters. The position peaked at $6.94M in Q1 2015. 32 funds tracked by Wall St. Rank hold EPRS as of Q2 2016.
- Broadfin Capital reported no remaining Epirus Biopharmaceuticals position as of Q2 2016 after selling out during the quarter.
- Broadfin Capital sold 1,079,543 Epirus Biopharmaceuticals shares in Q2 2016, an estimated $2.9M.
- Broadfin Capital first reported a position in Epirus Biopharmaceuticals in Q1 2015 and held it in 5 quarters.
- Broadfin Capital's Epirus Biopharmaceuticals position peaked at $6.94M in Q1 2015.
- 32 funds tracked by Wall St. Rank held Epirus Biopharmaceuticals as of Q2 2016.
Based on Broadfin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.